A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

NCT06999031 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory
Multiple Myeloma

Interventions

BIOLOGICAL: BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell

Sponsor

The First Affiliated Hospital of Nanchang University

Collaborators

[object Object]